

Media Release

Zug, 27 October 2014

Probiodrug accomplishes Initial Public Offering at Amsterdam's Euronext

Probiodrug, a privately held company in the portfolio of HBM Healthcare Investments, last week announced the successful completion of the intended initial public offering (IPO). The company raised a total of EUR 22.5 million through the issuance of approximately 1.5 million shares at a price of EUR 15.25. Trading of the shares on the Euronext Stock Exchange in Amsterdam will start today under the symbol "PBD".

HBM Healthcare Investments holds approximately 767'000 shares or 11.4% of the company after completion of the IPO. On the basis of the issue price of EUR 15.25 per share, the carrying value of the investment in Probiodrug increases by almost EUR 4.7 million to EUR 11.7 million. Hence the net asset value per HBM-share (NAV) increased by CHF 0.60 and reached a new high of over CHF 124 per share as per 24 October 2014.

For further information, please contact Dr Andreas Wicki, tel.: +41 41 768 11 08, andreas.wicki@hbmhealthcare.com

About Probiodrug

Probiodrug AG, headquartered in Halle, Germany, is a biopharmaceutical company with a focus on the development of new therapeutic approaches for the treatment of Alzheimer's disease. The development approach of the company is aimed at a reduction of pyroglutamate-Abeta (pyroGlu-Abeta) to fight Alzheimer's. The clinical development of most advanced compound PQ912 is about to enter Phase 2a.

About Alzheimer's disease

Alzheimer's disease is a neurological degenerative disease and the most common form of dementia. Since Alzheimer's cannot be cured yet and as the neuronal degradation process progresses, affected patients increasingly need help of other people. Today, 35 million people

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

worldwide are living in this situation, and it is assumed that this number will double by 2030 and triple by 2050 (World Alzheimer Report 2013).

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of some 25 promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors, and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 | CH-6300 Zug | Tel: +41 41 768 11 08 | Fax: +41 41 768 11 09 | info@hbmhealthcare.com
www.hbmhealthcare.com